In the early, uncertain days of the coronavirus pandemic, scientists delivered one comforting pronouncement: The virus that ...

The following is a summary of “Development of a prediction model for in-hospital mortality in immunocompromised chronic kidney diseases patients with severe infection,” published in the February 2025 ...

Invivyd's bid to expand Pemgarda's EUA for COVID-19 treatment was denied by the FDA. The company will share new data on ...

The following is a summary of “60-day mortality and the role of SARS-CoV-2 in hospital admissions of immunocompromised patients during later Omicron period: a population-based study in Sweden,” ...

Tixagevimab-cilgavimab reduced risk for severe COVID-19 progression in patients with hematologic malignancies on anti-CD20 therapy during the early Omicron era.

Covid vaccinations may not be enough to protect immunocompromised people from infection even when they have generated ...

Pemgarda has a standing emergency use authorization as a prophylaxis for immunocompromised patients, but FDA’s stringent ...

Yearly administration of the influenza vaccine is the main strategy to prevent influenza in immunocompromised patients. Here, we reviewed the recent literature regarding the clinical significance ...

During the pandemic, researchers discovered that immunocompromised individuals had difficulty clearing the virus, even when ...

H.C. Wainwright maintains a Buy rating on Invivyd (IVVD) with a $10 price target after the FDA rejected its submission to expand Pemgarda’s ...

Invivyd (IVVD) announced that Invivyd’s request to expand the existing emergency use authorization for pre-exposure prophylaxis of COVID-19 EUA ...

Noroviruses are increasingly recognized as an important cause of chronic gastroenteritis in immunocompromised patients, as reflected by the growing number of clinical case reports. This review ...